Generation Bio (NASDAQ:GBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Generation Bio (NASDAQ:GBIO) to a sell rating in a report released on Saturday.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Thursday, January 22nd. Citigroup restated a “market perform” rating on shares of Generation Bio in a research note on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price objective on shares of Generation Bio in a research note on Friday, November 7th. Wedbush set a $5.50 target price on Generation Bio and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Finally, Zacks Research raised Generation Bio to a “hold” rating in a research report on Monday, January 26th. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Generation Bio has an average rating of “Hold” and an average target price of $8.88.

Generation Bio Stock Performance

GBIO stock opened at $5.34 on Friday. The firm has a 50-day simple moving average of $5.53 and a two-hundred day simple moving average of $5.64. Generation Bio has a one year low of $3.00 and a one year high of $8.20. The firm has a market cap of $35.99 million, a price-to-earnings ratio of -0.57 and a beta of 2.05.

Hedge Funds Weigh In On Generation Bio

Hedge funds have recently bought and sold shares of the business. Y Intercept Hong Kong Ltd purchased a new position in Generation Bio during the second quarter valued at $47,000. DRW Securities LLC acquired a new position in shares of Generation Bio during the 4th quarter worth about $249,000. SymBiosis Capital Partners LLC purchased a new position in Generation Bio in the 4th quarter valued at about $3,777,000. Geode Capital Management LLC boosted its holdings in Generation Bio by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 51,795 shares of the company’s stock worth $294,000 after buying an additional 1,990 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Generation Bio by 54.3% during the 1st quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock worth $468,000 after buying an additional 407,843 shares in the last quarter. Hedge funds and other institutional investors own 95.22% of the company’s stock.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.